(Q38106994)

29 August 2017

Sorafenib for ovarian cancer (English)

1 reference

29 August 2017

1 reference

4

Simone Ferrero

1 reference

29 August 2017

Umberto Leone Roberti Maggiore

series ordinal

1

1 reference

29 August 2017

Mario Valenzano Menada

series ordinal

2

1 reference

29 August 2017

Pier Luigi Venturini

series ordinal

3

1 reference

29 August 2017

language of work or name

English

0 references

publication date

15 May 2013

1 reference

Expert Opinion on Investigational Drugs

29 August 2017

1 reference

29 August 2017

22

1 reference

29 August 2017

8

1 reference

29 August 2017

1049-1062

1 reference

Ovarian cancer: etiology, risk factors, and epidemiology

29 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.802769

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.802769

Overview of anti-angiogenic agents in development for ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.802769

Carcinoma of the ovary. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.802769

Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.802769

Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.802769

Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.802769

Ovarian cancer, version 3.2012.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.802769

Practical considerations in ovarian cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.802769

Intraperitoneal cisplatin and paclitaxel in ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.802769

Results of the 2006 Innsbruck International Consensus Conference on intraperitoneal chemotherapy in patients with ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.802769

A phase 3 trial of bevacizumab in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.802769

Incorporation of bevacizumab in the primary treatment of ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.802769

Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.802769

OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.802769

New strategies in the treatment of ovarian cancer: current clinical perspectives and future potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.802769

Major clinical research advances in gynecologic cancer in 2012.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.802769

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.802769

Targeting Raf-kinase: molecular rationales and translational issues.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.802769

Signal transduction pathways involving the Raf proto-oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.802769

The ERK cascade: a prototype of MAPK signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.802769

Raf kinases in cancer-roles and therapeutic opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.802769

VEGF-targeted therapy: mechanisms of anti-tumour activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.802769

Induction of angiogenesis during the transition from hyperplasia to neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.802769

Angiogenesis as a therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.802769

Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.802769

Vascular patterning defects associated with expression of activated Notch4 in embryonic endothelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.802769

Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.802769

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.802769

Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.802769

Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.802769

Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.802769

Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.802769

Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.802769

Combination therapy: intermittent sorafenib with bevacizumab yields activity and decreased toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.802769

Sorafenib in combination with weekly topotecan in recurrent ovarian cancer, a phase I/II study of the Hoosier Oncology Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.802769

Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.802769

Sorafenib in combination with carboplatin and paclitaxel as neoadjuvant chemotherapy in patients with advanced ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.802769

Sorafenib in combination with gemcitabine in recurrent epithelial ovarian cancer: a study of the Princess Margaret Hospital Phase II Consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.802769

Recent progress in the diagnosis and treatment of ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.802769

Antiangiogenic therapy for ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.802769

Selected combination therapy with sorafenib: a review of clinical data and perspectives in advanced solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.802769

Sorafenib in liver cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.802769

21 January 2018

Sorafenib in melanoma

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.802769

Sorafenib for the treatment of renal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.802769

Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.802769

Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.802769

Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.802769

Lack of reliability of CA125 response criteria with anti-VEGF molecularly targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.802769

Potential benefit of Sunitinib in recurrent and refractory ovarian clear cell adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.802769

Sorafenib efficacy in ovarian clear cell carcinoma revealed by transcriptome profiling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.802769

A Case of Stage III c Ovarian Clear Cell Carcinoma: The Role for Predictive Biomarkers and Targeted Therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.802769

Complete remission of recurrent ovarian clear cell carcinoma by chemotherapy with bevacizumab, trabectedin and oxaliplatin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.802769

10.1517/13543784.2013.802769

21 January 2018

Identifiers

DOI

1 reference

29 August 2017

1 reference